bluebird bio

Activities: Research & Development

Trending Articles

  1. Counteracting counterfeits in the pharmaceutical supply chain Sreedhar Patnala, General Manager at Systech, discusses the comprehensive benefits of embracing traceability
  2. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Industrial data mastery: navigating the 2025 landscape As industrial manufacturers contend with the ever-increasing volume and variety of operational data, the year ahead promises both complexity and opportunity
  4. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  5. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Manufacturing

Minaris to manufacture Bluebird Bio therapy for CALD

Early Cerebral Adrenoleukodystrophy is a life-threatening progressive neurodegenerative disease
Ingredients

Refined commercial production spec gets gene therapy EMA go-ahead

US-based Bluebird Bio is working with German apceth Biopharma for commercial manufacturing of its one-time thalassemia therapy that is approved in the EU, not the US
Regulatory

Apceth bullish on manufacturing deal with bluebird bio

The German CDMO will operate as commercial manufacturer in Europe for Zynteglo, bluebird bio's first gene therapy to gain regulatory approval
Manufacturing

Bluebird bio opens lentiviral vector manufacturing facility

The US company’s first facility will produce clinical and commercial supplies of gene therapy vectors, with room for expansion
Pharmaceutical

Collaboration to develop gamma delta CAR T cell product candidates

bluebird bio and Scottish immunotherapy company TC BioPharm, announced a strategic collaboration and license agreement focused on gamma delta CAR T cells
Research & Development

Lonza and Bluebird Bio announce commercial manufacturing agreement

For Lenti-D and LentiGlobin therapies for severe genetic diseases and T cell-based immunotherapies for cancer
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Homing in on cancer targets

Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Subscribe now